Natus Medical (NASDAQ: NTUS) will release its 2020 second quarter financial results on July 30, after market closure. A conference call for discussion and Q&A will occur at 1:30 PM PT (4:30 PM ET) the same day. Investors can participate via phone or online. The call will be archived on Natus's website for 90 days. Natus specializes in medical device solutions for diagnosing and treating central nervous and sensory system disorders for all ages.
Natus Medical Incorporated (NASDAQ: NTUS) announced its participation in the Raymond James Virtual Human Health Innovation Conference on June 16, 2020. CEO Jonathan Kennedy and CFO Drew Davies will hold one-on-one meetings with institutional investors. Interested investors can schedule meetings through a Raymond James representative. Natus specializes in medical device solutions for diagnosing and treating central nervous and sensory system disorders across all ages.
Natus Medical (NASDAQ: NTUS) has announced a partnership with Holberg EEG AS to advance the AutoSCORE algorithm, aimed at automating EEG classifications and improving reporting efficiency. This collaboration is expected to enhance the diagnosis and treatment of epilepsy patients globally. The AutoSCORE technology promises to reduce reporting variability and improve clinical outcomes. Holberg EEG has developed SCORE EEG, a software replacing traditional text reporting, making this partnership significant for the healthcare sector.
Natus Medical (NASDAQ: NTUS), a leader in medical device solutions for central nervous and sensory system disorders, announced that CEO Jonathan Kennedy and CFO Drew Davies will present at the UBS Virtual Global Healthcare Conference on May 19 at 2:10 p.m. Eastern Time. Investors can access the live webcast through the Company’s website, with a recording available for 30 days. Natus Medical focuses on innovative solutions for patients of all ages.